Literature DB >> 3992206

Treatment and prevention of recurrent staphylococcal furunculosis: clinical and bacteriological follow-up.

S A Hedström.   

Abstract

Various therapeutic and preventive methods were evaluated in 80 patients with recurrent staphylococcal furunculosis. The most appropriate treatment was peroral antibiotics for 10-14 days, mainly flucloxacillin twice daily. Fusidic acid ointment was used for prevention of relapses. Patients and healthy family members who carried the patient strain applied the ointment in nares twice daily every 4th week during 4-15 months. The method had a permanent effect in 80%. Implantation of strain 502 A was less effective when evaluated during a 2-3 yr period. 40-80 patients were checked up to 8 yr after their last furuncle. Three still had furuncles, in 2 of these cases the original strain was found in nares. 37 patients, now healthy after a mean observation time of 4.5 yr, showed either new nasal strains or negative cultures. A significantly lower frequency of phage group II strains in nares was noted in comparison to the previous findings during active furunculosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992206     DOI: 10.3109/00365548509070420

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

Review 1.  Staphylococcal skin infections in children: rational drug therapy recommendations.

Authors:  Shamez Ladhani; Mehdi Garbash
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Drug treatment of skin and soft tissue infections in elderly long-term care residents.

Authors:  B H Lertzman; A A Gaspari
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

3.  Community-acquired methicillin-resistant Staphylococcus aureus in institutionalized adults with developmental disabilities.

Authors:  Abraham Borer; Jacob Gilad; Pablo Yagupsky; Nechama Peled; Nurith Porat; Ronit Trefler; Hannah Shprecher-Levy; Klaris Riesenberg; Miriam Shipman; Francisc Schlaeffer
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.